Drug Trial Radar · NCT02190747
An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects
Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jul 14, 2014
Primary completion
May 23, 2016
Study completion May 23, 2016
Sponsor
- Lead sponsor
- Clementia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fibrodysplasia ossificans progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. Mouse models of FOP have demonstrated the ability of retinoic acid receptor (RAR) gamma agonists to prevent heterotopic ossification (HO) following injury. The purpose of the study is to evaluate whether palovarotene, an RAR gamma agonist, will prevent HO during and following a flare-up in subjects with FOP.
Conditions
- Fibrodysplasia Ossificans Progressiva
Interventions
PalovaroteneDrug
Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Responders at Week 6Time frame: Baseline (Day 1) and Week 6 (Day 42)
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Francisco, Division of Endocrinology and Metabolism
San Francisco, California
University of Pennsylvania, Center for Research in FOP & Related Disorders
Philadelphia, Pennsylvania
Hôpital Necker-Enfants Malades, Department of Genetics
Paris, France
The Royal National Orthopaedic Hospital, Brockley Hill
Stanmore, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.